OTC · GTHR
GeneThera, Inc.
Healthcare · Biotechnology
$0.00
Up+$0.00 (+0.00%)
Updated Sep 12, 2026, 7:59 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.53K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.05
- Volume
- 5K
- Avg. volume
- 2.94K
Price performance
GTHR price history
1M range · 0 trading sessions · Daily adjusted prices
GTHR does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest GTHR news
The latest Smart Investors Daily articles mentioning GTHR.
Stock researchCompany · Overview
GTHR research
Overview
Company profile and research snapshot.
Company profile
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
